RxDoctor Payments Data

Ziad Elghoul, MD

Interventional Cardiology · Chandler, AZNPI 1497787642

Payments from drug & device makers

$4,764in general payments, 2019–2025

Across 78 payments — averaging $61.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$1K
  • Boston Scientific$898
  • Medtronic$690
  • Baxter Healthcare$276
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$231
  • Welch Allyn$220
  • plus $1K from 20 others

What the payments were for

  • Travel & lodging$2,51753%
  • Food & beverage$1,73736%
  • Education$140%
  • Other$49610%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,764 in reported general payments places this provider in the 25th percentile of 223 interventional cardiology providers in Arizona.

See all interventional cardiology providers in Arizona

Medicare billing

Part B allowed, 2024
$1,873,877
Medicare patients
2,772
Services billed
16,738

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban904$937,523
XareltoRivaroxaban369$392,175
EntrestoSacubitril/Valsartan175$188,749
JardianceEmpagliflozin59$51,041
Repatha SureclickEvolocumab61$45,679
MultaqDronedarone Hcl34$42,465
Praluent PenAlirocumab31$17,316
FarxigaDapagliflozin Propanediol11$14,647
Metoprolol Succinate1,097$13,022
BrilintaTicagrelor15$10,319
Ranolazine ErRanolazine72$9,762
LivaloPitavastatin Calcium17$8,560
Atorvastatin Calcium796$7,529
Repatha SyringeEvolocumab15$7,463
Flecainide Acetate167$7,009

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$62$937,523904 claims
Johnson & JohnsonXarelto$124$392,175369 claims
NovartisEntresto$32$188,749175 claims
Boehringer IngelheimJardiance$80$51,04159 claims
Sanofi-aventis U.S. LLCMultaq$23$42,46534 claims
AstraZenecaFarxiga, Brilinta$35$24,96626 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 223 interventional cardiology providers in Arizona.

Other interventional cardiology in Chandler

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →